These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25949071)

  • 1. Diabetic retinopathy and systemic factors.
    Frank RN
    Middle East Afr J Ophthalmol; 2015; 22(2):151-6. PubMed ID: 25949071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.
    Wright AD; Dodson PM
    Eye (Lond); 2011 Jul; 25(7):843-9. PubMed ID: 21436845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
    Chew EY; Davis MD; Danis RP; Lovato JF; Perdue LH; Greven C; Genuth S; Goff DC; Leiter LA; Ismail-Beigi F; Ambrosius WT;
    Ophthalmology; 2014 Dec; 121(12):2443-51. PubMed ID: 25172198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of medical therapies on retinopathy progression in type 2 diabetes.
    ; ; Chew EY; Ambrosius WT; Davis MD; Danis RP; Gangaputra S; Greven CM; Hubbard L; Esser BA; Lovato JF; Perdue LH; Goff DC; Cushman WC; Ginsberg HN; Elam MB; Genuth S; Gerstein HC; Schubart U; Fine LJ
    N Engl J Med; 2010 Jul; 363(3):233-44. PubMed ID: 20587587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial.
    Bonora BM; Albiero M; Morieri ML; Cappellari R; Amendolagine FI; Mazzucato M; Zambon A; Iori E; Avogaro A; Fadini GP
    Diabetologia; 2021 Oct; 64(10):2334-2344. PubMed ID: 34368894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
    Keech AC; Mitchell P; Summanen PA; O'Day J; Davis TM; Moffitt MS; Taskinen MR; Simes RJ; Tse D; Williamson E; Merrifield A; Laatikainen LT; d'Emden MC; Crimet DC; O'Connell RL; Colman PG;
    Lancet; 2007 Nov; 370(9600):1687-97. PubMed ID: 17988728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate.
    Simó R; Hernández C
    Rev Recent Clin Trials; 2012 Feb; 7(1):71-80. PubMed ID: 21864248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?
    Dodson PM
    Eye (Lond); 2009 May; 23(5):997-1003. PubMed ID: 19169236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate and Diabetic Retinopathy.
    Knickelbein JE; Abbott AB; Chew EY
    Curr Diab Rep; 2016 Oct; 16(10):90. PubMed ID: 27525681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Diabetic Retinopathy Outcomes: FIELD Fenofibrate.
    Kalra S; Sahay R
    J Assoc Physicians India; 2018 Dec; 66(12):55-57. PubMed ID: 31313550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate - a potential systemic treatment for diabetic retinopathy?
    Wong TY; Simó R; Mitchell P
    Am J Ophthalmol; 2012 Jul; 154(1):6-12. PubMed ID: 22709833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed messages on systemic therapies for diabetic retinopathy.
    Lim LS; Liew G; Cheung N; Mitchell P; Wong TY
    Lancet; 2010 Oct; 376(9751):1461; author reply 1462. PubMed ID: 21036265
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipids and Diabetic Retinopathy.
    Modjtahedi BS; Bose N; Papakostas TD; Morse L; Vavvas DG; Kishan AU
    Semin Ophthalmol; 2016; 31(1-2):10-8. PubMed ID: 26959124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic medical management of diabetic retinopathy.
    Lingam G; Wong TY
    Middle East Afr J Ophthalmol; 2013; 20(4):301-8. PubMed ID: 24339679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in risk of progression of diabetic retinopathy.
    Klein BE
    N Engl J Med; 2010 Jul; 363(3):287-8. PubMed ID: 20587586
    [No Abstract]   [Full Text] [Related]  

  • 16. Systemic association of newly diagnosed proliferative diabetic retinopathy among type 2 diabetes patients presented at a tertiary eye hospital of Nepal.
    Thapa R; Bajimaya S; Sharma S; Rai BB; Paudyal G
    Nepal J Ophthalmol; 2015; 7(1):26-32. PubMed ID: 26695602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenofibrate and diabetic retinopathy.
    Fagan XJ; Chong EW
    Clin Exp Ophthalmol; 2015; 43(4):297-9. PubMed ID: 26099043
    [No Abstract]   [Full Text] [Related]  

  • 18. Medical management for the prevention and treatment of diabetic macular edema.
    Kiire CA; Porta M; Chong V
    Surv Ophthalmol; 2013; 58(5):459-65. PubMed ID: 23969020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should we start all patients with diabetic retinopathy on fenofibrates?
    Koshy J; Koshy JM; Thomas S; Kaur G; Mathew T
    Middle East Afr J Ophthalmol; 2013; 20(4):309-14. PubMed ID: 24339680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and risk factors of diabetic retinopathy in subjects with suboptimal glycemic, blood pressure and lipid control. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, Report 33).
    Raman R; Gupta A; Kulothungan V; Sharma T
    Curr Eye Res; 2012 Jun; 37(6):513-23. PubMed ID: 22577770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.